Signal transducing adaptor protein-2 (STAP-2) is a recently identified adaptor protein that contains pleckstrin and Src homology 2 (SH2)-like domains as well as a YXXQ motif in its C-terminal region. Our previous study in T cells demonstrated that STAP-2 influences FAK protein levels through recruitment of E3 ubiquitin ligase, Cbl, to FAK.
Introduction
Signal transducing adaptor protein-2 (STAP-2), whose human homolog is identical to a recently cloned adaptor molecule, BKS, a substrate of Brk (breast tumor kinase) is expressed in a variety of tissues and cells, such as lymphocytes, macrophages and hepatocytes, and its abundant expression pattern has suggested a wide range of functions in vivo [1; 2] . STAP-2 contains an N-terminal pleckstrin homology (PH) region, a YXXQ motif in its C-terminal region and a region distantly related to the SH2 domain and the proline-rich, tyrosine phosphorylation motifs. Through these functional domains, STAP-2 can bind to a number of signaling molecules and regulate the activities of its binding partners. For example, STAP-2 interacts with STAT3 through its YXXQ motif [1] and with STAT5 through its PH and SH2-like domains [3] , resulted in influencing their transcriptional activity. The SH2-like domain of STAP-2 binds to MyD88 and IKK-a/b, thereby modulating TLR4-mediated cytokine production and NFkB activation [4] . Both the SH2-like domain and the C-terminal proline-rich region of STAP-2 are required for the binding to PLC-g1, and the interaction leads to negative regulation of FceRI-mediated signals [5] . Although STAP-2-knockout mice did not show severe abnormalities, LPS-or IL-6-stimulated acute phase protein gene induction was significantly decreased in STAP-2-deficient hepatocytes. In addition, STAP-2-deficient T cells showed the increased FAK protein content and the enhanced adhesion to fibronectin [6] . The above information is likely to indicate the critical involvement of STAP-2 in the processes of immune and inflammatory responses.
Despite of clarifying STAP-2 as the characteristics of an adaptor protein, the regulatory mechanisms for STAP-2 itself are largely unknown. In this manuscript, we 4 have found that STAP-2 protein is degraded dependently of Casitas B-lineage Lymphoma (Cbl) protein. Cbl is composed of an N-terminal tyrosine-kinase-binding domain, ring-finger motif, a proline-rich region and a C-terminal ubiquitin-associated domain. Cbl is believed to function mainly as a negative regulator of signal transduction pathways, largely via its E3 ubiquitin ligase activity. Cbl mediates degradation of various receptors, kinases and signaling molecules, such as EGF receptor [7] , STAT5 [8] and Syk [9] .
In the present study, we found that STAP-2 physically interacted with Cbl through its PH and SH2-like domains. Small-interfering RNA (siRNA)-mediated reduction of endogenous Cbl elevated STAP-2 protein levels. In contrast, over-expression of Cbl induced STAP-2 degradation. Furthermore, Cbl-mediated regulation of STAP-2 protein levels affected Brk/STAP-2-induced STAT3 activation. Therefore, our findings propose a novel regulatory mechanism of STAP-2, an important modulator of both immune and inflammatory systems.
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Material and Methods
Reagents and antibodies
The proteasome inhibitor MG132 was purchased from Peptide Institute (Osaka, Japan).
Cycloheximide (CHX) was purchased from WAKO Chemicals (Osaka, Japan). FLAGtagged Brk and STAT3-LUC were provided by Dr. A. Harvey (Brunel University, Middlesex, UK), Dr. T. Hirano(Osaka University, Osaka, Japan), respectively [10; 11] .
Expression vectors for epitope-tagged STAP-2, glutathione S-transferase (GST)-fusion STAP-2 mutants (GST-STAP-2 PH (1-147 aa), GST-STAP-2 SH2 (148-243 aa), and GST-STAP-2 C (244-403 aa)), Myc-tagged Cbl constructs were described previously [6, 12] . Anti-Cbl, anti-GST and anti-STAT3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-actin, anti-Myc, anti-FLAG M2 antibody and rabbit polyclonal anti-FLAG antibody were purchased from Sigma (St Louis, MO).
Cell culture, transfection and luciferase assays
Human T-cell leukemia cell line, Jurkat was maintained in RPMI1640 medium supplemented with 10% fetal calf serum (FCS). Human embryonic kidney carcinoma cell line 293T, human hepatoma cell line Hep3B and human cervix carcinoma cell line HeLa were maintained in DMEM containing 10% FCS. Stable transformants expressing Myc-tagged STAP-2 in Jurkat [3] , HeLa [13] and Hep3B [14] were established as described previously and maintained in the above medium in the presence of G418 (0.5 mg/ml). 293T was transfected by the standard calcium precipitation protocol. Luciferase assay was performed as described [3] . At 36 h after transfection, the cells were lysed in 50 _l of Reporter Lysis Buffer (Promega, Madison, WI) and assayed for luciferase 6 activities according to the manufacturer's instructions. Luciferase activities were normalized to the b-galactosidase activities. Three or more independent experiments were carried out for each assay. HeLa was transfected using jetPEI (Polytransfection, Illkirch, France). At 36 h after transfection, the cells were harvested and assayed for the luciferase activity using the Dual-Luciferase Reporter Assay System (Promega). Three or more independent experiments were carried out for each assay. 
Transfection of Small
Immunoprecipitation and immunoblotting
The immunoprecipitation and Western blotting assays were performed as described previously [3] . The cells were harvested and lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 mM sodium orthovanadate and 1 mM phenylmethylsulfonyl fluoride). The immunoprecipitates from cell lysates were resolved on SDS-PAGE and transferred to PVDF transfer membrane (PerkinElmer; Boston, MA). The filters were then immunoblotted with each antibody. Immunoreactive proteins were visualized using an enhanced chemiluminescence detection system (Millipore; Bedford, MA). 
Statistical methods
The significance of differences between group means was determined by Student's ttest.
8
Results and discussion
Cbl directly interacts with STAP-2
We previously demonstrated that STAP-2-expressing Jurkat T cells show an enhanced with Myc-tagged Cbl. The binding potential of these mutant proteins with Cbl was examined by pull-down assays with glutathione-sepharose, followed by western blot analysis with an anti-Myc antibody (Fig. 1D) . The precipitates of the GST-STAP-2 PH and SH2-like proteins contained Cbl protein, but no Cbl protein was detected in the GST-STAP-2 C precipitate. Therefore, the PH and SH2-like domains of STAP-2 are able to interact with Cbl.
Cbl regulates STAP-2 protein levels
Cbl regulates the levels of various proteins through its E3 ubiquitin ligase activity.
Therefore, to assess the functional relevance of interaction between STAP-2 and Cbl, we focused on the proteasome-dependent degradation of STAP-2 by Cbl. To this end, we used siRNA to reduce endogenous expression of Cbl in several STAP-2 expressing transformants (HeLa/STAP-2, Hep3B/STAP-2 and Jurkat/STAP-2). These transformants were transfected with a specific siRNA for Cbl or with a control siRNA. Total cellular proteins from the transfected cells were subjected to western blot analysis, which confirmed a reduction of Cbl protein levels. As shown in Fig. 2A , siRNA-mediated knockdown of Cbl in these cells resulted in a significant increase of STAP-2 protein levels compared with control siRNA-transfected cells. We also tested the effect of CHX, using siRNA-transfected HeLa cells, to confirm whether Cbl is endogenously involved in STAP-2 stability. As shown in Fig. 2B , Cbl siRNA-transfected HeLa cells showed enhanced stability of endogenous STAP-2 even in the presence of CHX. These results indicate that Cbl controls STAP-2 protein levels via proteasomal degradation. Moreover, the treatment of HeLa cells with MG132, an inhibitor of proteasome-dependent degradation, resulted in an enhancement of STAP-2 protein levels (Fig. 2C) .
Importantly, efficient co-expression of STAP-2 with Cbl in 293T cells induced a marked decrease of STAP-2 protein levels, which was recovered by the treatment of MG132 (Fig. 2D) . These results indicate that the protein level of STAP-2 is endogenously controlled by Cbl via the proteasome degradation pathway.
Cbl negatively regulates Brk/STAP-2-mediated STAT3 activation through degradation of STAP-2
To elucidate whether the degradation of STAP-2 by Cbl has any functional significance, with an enhancement of STAT3 activity but did not affect Brk protein levels (Fig. 3A, lower panels). We next examined whether Cbl expression had any effects on STAP-2/Brk-mediated STAT3 activation. STAP-2/Brk-mediated STAT3 activation was suppressed by Cbl in a dose-dependent manner (Fig. 3B) , in parallel with a reduction of STAP-2 protein levels (Fig. 3B, lower panel) , although Cbl expression had no effect on the protein levels of STAT3 (data not shown). Similar results were obtained from the same experiments using 293T cells (data not shown). These data indicate that 11 degradation of STAP-2 by Cbl resulted in a decrease of STAT3 activation by Brk/STAP-2. We further tested whether this effect was recovered by treatment with MG132. As shown in Fig. 3C , the Cbl-mediated reduction of Brk/STAP-2-mediated STAT3 activation and STAP-2 protein levels were restored by treatment with MG132. To further verify the role of endogenous Cbl in Brk/STAP-2-mediated STAT3 activation, we tested the effect of Cbl siRNA on Brk-induced STAT3-LUC activation in HeLa/STAP-2 transformants. In HeLa/STAP-2 cells, Brk expression induced STAT3 activation in a dose-dependent manner (Fig. 3D) . siRNA-mediated reduction of endogenous Cbl expression resulted in a significant enhancement of Brk-induced STAT3-LUC activation in these cells (Fig. 3D, upper panel) . Importantly, the protein levels of STAP-2 were also increased by Cbl knockdown (Fig. 3D, lower panel) . No significant alteration of Brk protein levels was observed by Cbl knockdown. These results indicate that Cbl regulates STAP-2 activity via proteasomal degradation.
12
Concluding remarks
Although the biological activities of signaling molecules can be determined, in part, by regulating their levels through protein degradation, activation-induced protein degradation may help to eliminate activated signaling molecules, thus attenuating signaling. Previously, we have shown that STAP-2 shows the characteristics of an adaptor protein that can interact with several other signaling molecules and that it regulates a variety of signaling pathways. However, only tyrosine-phosphorylation of STAP-2 has been demonstrated to modulate its functions [14] . In this study, we demonstrated, for the first time, a mechanism that regulates STAP-2 activity through Cbl-mediated proteasome-dependent degradation. The results of the present study clearly indicate that STAP-2 is constitutively degraded via interaction with Cbl and that a proteasome inhibitor blocks the degradation of STAP-2. Importantly, Cbl-mediated regulation of STAP-2 protein levels controls Brk/STAP-2-induced STAT3 activation.
We have previously shown that STAP-2 induces proteasomal degradation of FAK by recruiting Cbl, resulting in a decrease of T cell adhesion to fibronectin [6] . This finding suggests that the STAP-2-Cbl axis may regulate T cell receptor (TCR)-mediated signaling, although, we do not know at present whether STAP-2 interacts with other signaling molecules downstream of the TCR. Another adaptor protein, Src-like adaptor protein-2 (SLAP-2), which possesses a short amino-terminal region followed by SH3 and SH2 domains, is reported to be involved in the regulation of T cell receptor signaling though Cbl [17, 18] . SLAP-2 interacts with Cbl through its carboxy-terminal region and negatively regulates tyrosine kinase activity of ZAP-70 in a proteasome degradation-dependent manner [18] .
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STAP-2 is tyrosine-phosphorylated by epidermal growth factor (EGF) in NIH-3T3 cells [1] . Cbl also plays a critical role in the EGF/EGF receptor signaling pathway [7, 19] . Therefore, STAP-2 may participate in the regulation of EGF/EGF receptor signaling pathways through Cbl. We have also previously demonstrated that STAP-2 negatively regulates the c-Fms-mediated signaling pathway in macrophages [20] . Cbl 
